New York, NY – [Date of Publication] – In a landmark development set to revolutionize personal mobility, Wandercraft, a leading innovator in medical robotics, has officially announced the U.S. commercial launch of Eve, the world’s first FDA-cleared self-balancing personal exoskeleton. This groundbreaking device is now available for eligible adults living with spinal cord injuries (SCI) at any neurological level, offering an unprecedented opportunity for hands-free upright mobility. The announcement marks a pivotal moment for individuals who rely on wheelchairs, promising enhanced independence and a dramatically improved quality of life.
The introduction of Eve to the American market signifies a profound leap forward in assistive technology. Unlike conventional exoskeletons that necessitate the use of crutches or walkers for stability, Eve leverages sophisticated physical AI to maintain balance independently. This innovative feature empowers users to engage in a wide array of daily activities with their hands free – from preparing meals and opening doors to carrying objects and interacting with their environment in a more natural, upright posture. Wandercraft emphasizes that Eve is designed to complement, rather than replace, a wheelchair, providing a flexible and powerful additional mobility option for moments when standing and walking are desired.
Main Facts: Hands-Free Upright Mobility Becomes a Reality
Wandercraft’s Eve exoskeleton has emerged from years of rigorous research and development, culminating in its FDA clearance and subsequent commercial availability. The core innovation lies in its unique self-balancing technology, powered by advanced physical artificial intelligence. This distinguishes Eve from its predecessors and competitors, which typically require external aids for user stability. For individuals with spinal cord injuries, the ability to stand and move without the constant preoccupation of maintaining balance represents a monumental shift.
Key features and benefits of Eve include:
- Self-Balancing Technology: Eliminates the need for crutches or walkers, freeing users’ hands.
- Hands-Free Operation: Enables participation in daily activities such as reaching, carrying, cooking, and interacting socially at eye level.
- Broad Eligibility: Cleared for adults with spinal cord injuries at any neurological level, a significant expansion over previous devices. Eligibility is primarily based on the ability to safely operate the device’s controller and absence of contraindications.
- Personalized Experience: Each Eve device is individually fitted and manufactured, followed by a customized training program and ongoing support.
- Complementary Mobility: Designed to work alongside a wheelchair, offering users diverse options for navigating their world.
The commercial launch in the U.S. follows extensive clinical validation and usability testing, providing a robust body of evidence to support Eve’s safety and efficacy. This milestone is not merely the release of a new product; it is the opening of a new chapter for thousands of individuals seeking greater autonomy and inclusion.
A Journey of Innovation: The Road to Commercialization
Chronology of Development and Regulatory Milestones
The path to Eve’s U.S. commercial launch has been a testament to Wandercraft’s unwavering commitment to innovation and patient-centric design. The company has dedicated years to the intricate development of its robotics, specifically focusing on the complex challenges of dynamic balance and intuitive user control for individuals with severe mobility impairments.
The journey began with foundational research into bipedal robotics and advanced control algorithms. Recognizing the critical need for a hands-free solution, Wandercraft invested heavily in developing "physical AI" – a sophisticated system that enables the exoskeleton to dynamically adapt to various terrains and user movements, anticipating and correcting for imbalances in real-time. This technology is a significant departure from earlier exoskeleton designs, which often relied on more static balance systems or required user input for stability.
A crucial turning point was the attainment of FDA clearance. This rigorous regulatory approval process involved comprehensive submissions detailing Eve’s design, safety mechanisms, clinical evidence, and usability testing. The fact that Eve secured clearance without restrictions based on the neurological level of spinal cord injury underscores the breadth and depth of the data presented to the FDA. This achievement broadened the potential user population considerably, reflecting the device’s robust safety profile and versatile capabilities.
Following FDA clearance, Wandercraft meticulously established the necessary infrastructure to support a nationwide commercial launch. This included developing a comprehensive user acquisition process, from initial clinical evaluation and trials to individualized fitting, manufacturing, and a personalized training program. The company also forged strategic partnerships with key players in the complex rehabilitation technology (CRT) sector and healthcare providers to ensure seamless access and ongoing support for users.
The U.S. commercial launch was formally celebrated at an event in New York City, co-hosted with the United Spinal Association, coinciding with their 80th anniversary. This celebratory gathering brought together a diverse group including individuals living with spinal cord injuries, clinicians, researchers, disability advocates, policymakers, Eve test pilots and their families, and Wandercraft leadership. Live demonstrations of Eve in action provided a powerful visual testament to its capabilities, showcasing the tangible benefits of hands-free upright mobility. This event served not only as a launch but also as a powerful affirmation of the collective effort to advance accessibility and independence.
Unpacking the Technology and Its Impact: Supporting Data and Evidence
The Breakthrough of Physical AI and Self-Balancing
At the heart of Eve’s revolutionary capabilities is its advanced physical AI. This isn’t just about automated movements; it’s about intelligent, real-time adaptation. The system continuously monitors the user’s posture, weight distribution, and intended movements, making micro-adjustments to the exoskeleton’s joints and actuators to maintain stability. This mimicry of human balance mechanisms allows users to move freely without needing to rely on their upper limbs for support, a limitation that has historically constrained the utility of other exoskeletons.
The significance of this self-balancing feature cannot be overstated. For individuals with SCI, the ability to use their hands for everyday tasks while standing or walking opens up a new realm of possibilities. Simple actions like reaching for an item on a high shelf, carrying a tray, opening a door, or even participating in a conversation at eye level become achievable without compromising stability. This not only enhances functional independence but also fosters greater social inclusion and reduces physical strain on caregivers.
Furthermore, Eve’s FDA clearance without neurological level restrictions is a critical differentiator. Previous exoskeleton technologies often had stringent criteria, limiting use to individuals with specific levels of intact motor function. Wandercraft’s ability to demonstrate safety and efficacy for a broader population – contingent only on the ability to safely operate the controller and absence of contraindications – is a testament to the device’s inherent stability and sophisticated control system. This expanded eligibility reflects the extensive safety data, robust clinical evidence, and comprehensive usability testing that underpinned Wandercraft’s successful FDA submission. It represents a commitment to inclusivity, ensuring that more individuals can benefit from this life-changing technology.
Rigorous Research Paves the Way for Personal Use
The commercial availability of Eve is underpinned by a strong foundation of peer-reviewed research, validating its efficacy and safety for personal use. These studies have been instrumental in demonstrating that individuals with high-level spinal cord injuries, along with their companions, can be effectively trained to utilize the self-balancing exoskeleton in real-world scenarios.
One pivotal study, published in the Journal of Visualized Experiments (JoVE), detailed findings from research conducted at Kessler Foundation and the James J. Peters VA Medical Center. This research specifically investigated the training protocol for individuals with tetraplegia and high paraplegia to use a self-balancing exoskeleton for personal mobility. Among the initial 16 participants who completed the protocol, the results were highly encouraging:
- Performance Goals Met: All participants successfully achieved the study’s performance goals for both the Timed Up and Go (TUG) test – a measure of functional mobility – and the 6-Minute Walk Test (6MWT) – an indicator of walking endurance.
- Donning and Doffing Proficiency: A remarkable 15 out of 16 participants achieved the donning goal (putting on the exoskeleton) after just four training sessions, and all participants successfully achieved the doffing goal (taking it off).
- Safety Profile: Critically, the researchers reported no serious adverse events among the participants who completed the protocol, underscoring Eve’s safety in a controlled training environment.
These findings are crucial as they move beyond merely demonstrating the ability to stand or walk. As Gail Forrest, PhD, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, emphasized, "We examined whether people with high-level spinal cord injuries and their companions could learn to use a self-balancing exoskeleton and perform functional tasks relevant to personal use." This focus on practical, everyday application is what truly validates Eve’s readiness for commercial deployment and integration into users’ daily lives.
Further supporting data was presented at the Academy of Spinal Cord Injury Professionals (ASCIP) Annual Meeting. This presentation showcased results from the first 16 participant pairs in Wandercraft’s pivotal study, also conducted at James J. Peters VA Medical Center and Kessler Foundation. The findings reinforced the earlier research, indicating that Eve successfully supported safe, hands-free assisted walking for individuals with SCI, maintaining a low adverse-event rate. Participants also demonstrated high perceived safety, user satisfaction, and ease of training while performing key mobility tasks and activities of daily living. This cumulative evidence provides a robust scientific basis for Eve’s commercial launch, assuring both users and clinicians of its capabilities and safety.
The Comprehensive Path to Acquiring Eve
Wandercraft has established a meticulous and supportive process for individuals interested in obtaining Eve. This multi-stage journey ensures that each user is properly evaluated, fitted, and trained to maximize the benefits of the exoskeleton:
- Clinical Evaluation and Trial: Prospective users begin with a thorough clinical evaluation to assess their eligibility and suitability for the device. This includes a trial period where individuals can experience Eve firsthand under professional guidance.
- Physician’s Order: Following a successful trial and clinical assessment, a physician’s order is required, similar to other complex medical devices.
- Individualized Fitting and Manufacturing: Each Eve unit is custom-fitted and manufactured to the user’s specific anatomical measurements, ensuring optimal comfort, stability, and performance.
- Personalized Training Program: Users undergo a comprehensive training program with the Wandercraft team. This program is tailored to individual needs and capabilities, focusing on safe operation, functional tasks, and integration into daily routines.
- Ongoing Support: Post-delivery, Wandercraft provides continuous support, including technical assistance, maintenance, and further training as needed, ensuring a long-term positive experience.
This holistic approach underscores Wandercraft’s commitment not just to selling a device, but to enabling a sustainable transformation in mobility for its users.
Voices of Change: Official Responses and Personal Triumphs
Leadership’s Vision: Connecting People to the World
The launch of Eve is a culmination of years of dedicated effort, a point underscored by Matthieu Masselin, co-founder and CEO of Wandercraft. "FDA clearance showed that Eve was ready to move forward. Today is about making it a reality for the people we built it for," Masselin stated. His remarks highlight the intrinsic motivation behind Wandercraft’s mission: to translate advanced robotics into tangible improvements in human connection and quality of life.
Masselin further elaborated on the company’s broader vision, "We have spent years developing the robotics, but our breakthroughs only matter when we’re able to better connect people to the world around them. That’s why we built an infrastructure that supports people every step of the way, from evaluation and fitting to reimbursement, training, and ongoing service." This statement reflects a deep understanding that technological innovation alone is insufficient; a robust support ecosystem is essential to ensure that advanced medical devices reach those who need them most and are integrated effectively into their lives. Wandercraft’s commitment extends beyond engineering, embracing a comprehensive approach to user empowerment.
The User Experience: Freedom and Joy in Everyday Moments
The true impact of Eve is perhaps best articulated by those who have experienced its transformative potential firsthand. Caroline Laubach, a Wandercraft test pilot, shared a powerful testimony: "With Eve, being upright isn’t just about standing. It’s about having the freedom to use my hands, move through my home, and connect with people in a new way." Her words encapsulate the profound shift in independence and social interaction that Eve offers.
For individuals like Caroline, the seemingly simple act of standing freely and using one’s hands opens up a world of possibilities that were previously inaccessible or required significant assistance. This includes participating more actively in household chores, engaging in hobbies, and interacting with family and friends at eye level, fostering a greater sense of presence and dignity. "Those everyday moments bring me so much joy. What makes this milestone especially meaningful is knowing that more people will now have the chance to experience Eve for themselves and find that same joy in their own way," Laubach added. Her personal account underscores the emotional and psychological benefits of increased mobility, emphasizing that the joy derived from such independence is deeply personal and widely sought after.
Expanding Horizons: Implications for Accessibility, Healthcare, and Beyond
Building a Robust Ecosystem for Access and Support
The successful integration of a complex medical device like Eve into the lives of users requires a sophisticated and accessible distribution and support network. Wandercraft has strategically partnered with leading organizations to ensure comprehensive coverage across the U.S.
National Seating & Mobility (NSM) has been designated as Wandercraft’s exclusive Complex Rehabilitation Technology (CRT) distribution partner for Eve. NSM, with its extensive network of over 180 locations, will play a critical role in facilitating evaluations, providing user education, streamlining access, and overseeing delivery. CRT providers are indispensable in connecting users with the entire ecosystem of care, including clinicians, Assistive Technology Professionals (ATPs), payers, and other specialists. Their expertise ensures that individuals receive the individualized support necessary to transition from prescription to proficient personal use of a sophisticated mobility device.
Complementing this national network, Good Shepherd Rehabilitation in Pennsylvania’s Lehigh Valley will serve as a Wandercraft Center of Excellence. Good Shepherd has already developed deep expertise through its work with Wandercraft’s Atalante X, a rehabilitation-focused exoskeleton, and will now be the exclusive Eve partner in its region. At the Hyland Center, eligible users and their companions will have the opportunity to learn about and experience Eve technology. This regional hub will provide concentrated expertise and support, acting as a model for future access locations.
Furthermore, USVetServ, a Service-Disabled Veteran-Owned Small Business, has been appointed as an authorized independent distributor for both Eve and Atalante X for the U.S. Department of Veterans Affairs (VA). This partnership is vital for extending the benefits of Wandercraft’s technology to eligible veterans across VA medical centers and other facilities nationwide, acknowledging their unique needs and contributions.
To navigate the often-complex landscape of healthcare benefits and financing, Wandercraft has also established a dedicated access team. This team assists users and their care teams with understanding benefits, preparing necessary documentation, navigating reimbursement processes, exploring financing options, and coordinating with clinicians and payers. This comprehensive support system is crucial for making advanced technology accessible to a broader population.
Navigating Reimbursement: Making Advanced Technology Accessible
A significant barrier to the widespread adoption of advanced medical devices is often the cost and the intricacies of reimbursement. Wandercraft has made strides in addressing this challenge. For individuals who meet specific eligibility and medical necessity requirements, Medicare provides coverage for qualifying personal exoskeletons. These devices are classified as custom-fitted orthoses under HCPCS billing code K1007, subject to individual coverage requirements. This classification and coverage are vital steps toward making Eve financially accessible to a broader range of patients, recognizing the device’s therapeutic and functional benefits. Ongoing efforts will continue to ensure that private insurance providers also recognize and cover the Eve exoskeleton, further expanding access.
A Paradigm Shift in Spinal Cord Injury Care
The commercial launch of Eve signifies more than just the availability of a new product; it represents a paradigm shift in the management and rehabilitation of spinal cord injuries. The implications are far-reaching:
- Enhanced Quality of Life: By restoring hands-free upright mobility, Eve empowers individuals to participate more fully in social, professional, and personal activities, reducing dependency and fostering greater self-esteem.
- Improved Health Outcomes: Upright mobility can offer numerous physiological benefits, including improved circulation, bone density, bowel and bladder function, and reduced risk of pressure sores, which are common secondary complications of prolonged sitting.
- Evolution of Rehabilitation Practices: Eve’s capabilities will likely influence rehabilitation protocols, pushing the boundaries of what is considered achievable in recovery and long-term care for SCI patients.
- Greater Inclusion and Dignity: The ability to stand and move at eye level fundamentally changes how individuals with SCI interact with the world, promoting greater inclusion and a sense of dignity that comes from independent movement.
Looking Forward: The Future of Exoskeletons
The journey for Wandercraft and the Eve exoskeleton is just beginning. The commercial launch in the U.S. opens doors for continued innovation, refinement, and potentially, expansion into other global markets. As physical AI technology advances, future iterations of exoskeletons may become even more intuitive, versatile, and seamlessly integrated into daily life. The success of Eve will undoubtedly inspire further research and development in assistive robotics, paving the way for a future where mobility limitations are significantly reduced.
Wandercraft’s commitment to "connecting people to the world around them" is a powerful guiding principle. With Eve, the company is not just selling a device; it is delivering a promise of renewed independence, expanded possibilities, and the simple, profound joy of hands-free upright mobility. For those seeking to learn more about Eve or to request an evaluation, further information is available at www.wandercraft.eu/form. The future of personal mobility has arrived, and it is self-balancing.
